Lamy 10-Q quarterly reports

Exousia Bio, Inc. (formerly LAMY) has transitioned its business focus to clinical-stage biotechnology, specifically exosome therapeutics for oncology, and reported a net loss for the nine months ended February 28, 2026.

Exousia Bio, formerly LAMY, has pivoted to a clinical-stage biotechnology focus after acquiring Exousia AI, securing a $250,000 convertible note amidst a significant net loss and going concern warning.

LAMY, a development-stage company, reported no revenue and a significant increase in net loss for the quarter ended August 31, 2025, raising substantial doubt about its ability to continue as a going concern.

LAMY, a development-stage corporation focused on financial education through video games, reports a net income of $54,895 for the nine months ended February 28, 2025, following a change in control on December 6, 2024.

LAMY reports a net income of $80,659 for the six months ended November 30, 2024, alongside a significant change in ownership and control.

LAMY Inc. reports increased revenue for the quarter ended August 31, 2024, but continues to operate at a loss with substantial doubt about its ability to continue as a going concern.

LAMY Inc.'s Q3 2024 results show increased revenue but ongoing net losses and reliance on related party funding.

LAMY Inc.'s Q2 2024 filing reveals revenue generation alongside ongoing concerns about the company's ability to continue as a going concern.